Investors sold shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on strength during trading on Wednesday. $113.76 million flowed into the stock on the tick-up and $183.89 million flowed out of the stock on the tick-down, for a money net flow of $70.13 million out of the stock. Of all companies tracked, Regeneron Pharmaceuticals had the 0th highest net out-flow for the day. Regeneron Pharmaceuticals traded up $6.47 for the day and closed at $441.37

Several equities research analysts have recently issued reports on REGN shares. Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $436.00 to $415.00 in a research note on Friday, April 8th. Leerink Swann restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, April 9th. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 12th. Brean Capital restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 12th. Finally, Cowen and Company restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Sunday, April 17th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and fourteen have assigned a buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $508.92.

The stock has a 50-day moving average of $376.27 and a 200-day moving average of $390.25. The company has a market capitalization of $46.03 billion and a P/E ratio of 69.98.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.62 by $0.20. The company earned $1.21 billion during the quarter, compared to the consensus estimate of $1.24 billion. Equities research analysts predict that Regeneron Pharmaceuticals Inc. will post $10.82 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi purchased 64,731 shares of the company’s stock in a transaction that occurred on Tuesday, June 14th. The shares were acquired at an average cost of $363.86 per share, for a total transaction of $23,553,021.66. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joseph L. Goldstein sold 2,125 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the sale, the director now owns 15,125 shares in the company, valued at $6,428,125. The disclosure for this sale can be found here.

Other hedge funds have modified their holdings of the company. American International Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 0.4% in the fourth quarter. American International Group Inc. now owns 38,434 shares of the biopharmaceutical company’s stock worth $20,865,000 after buying an additional 136 shares during the period. BlackRock Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 8.3% in the fourth quarter. BlackRock Advisors LLC now owns 262,466 shares of the biopharmaceutical company’s stock worth $142,485,000 after buying an additional 20,224 shares during the period. Utah Retirement Systems raised its stake in shares of Regeneron Pharmaceuticals by 0.7% in the fourth quarter. Utah Retirement Systems now owns 14,152 shares of the biopharmaceutical company’s stock worth $7,683,000 after buying an additional 100 shares during the period. KBC Group NV raised its stake in shares of Regeneron Pharmaceuticals by 13.8% in the fourth quarter. KBC Group NV now owns 14,604 shares of the biopharmaceutical company’s stock worth $7,928,000 after buying an additional 1,767 shares during the period. Finally, Genesee Valley Trust Co. raised its stake in shares of Regeneron Pharmaceuticals by 4.1% in the fourth quarter. Genesee Valley Trust Co. now owns 2,972 shares of the biopharmaceutical company’s stock worth $1,613,000 after buying an additional 117 shares during the period.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.